Literature DB >> 10220611

Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. ACE inhibitors in the management of congestive heart failure: comparative economic data.

W L Boyko1, H A Glick, K A Schulman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10220611     DOI： 10.1016/s0002-8703(99)70443-6

Source DB:  PubMed          Journal:  Am Heart J        ISSN： 0002-8703            Impact factor:   4.749


× No keyword cloud information.
  5 in total

Review 1.  Pharmacoeconomic considerations in assessing and selecting congestive heart failure therapies.

Authors:  Emile Levy; Pierre Levy
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 2.  Value for money and the Quality and Outcomes Framework in primary care in the UK NHS.

Authors:  Simon Walker; Anne R Mason; Karl Claxton; Richard Cookson; Elisabeth Fenwick; Robert Fleetcroft; Mark Sculpher
Journal:  Br J Gen Pract       Date:  2010-05       Impact factor: 5.386

3.  ST-Segment Elevation Myocardial Infarction.

Authors:  Yerem Yeghiazarians; Peter H. Stone
Journal:  Curr Treat Options Cardiovasc Med       Date:  2002-02

Review 4.  Economic burden of heart failure in the elderly.

Authors:  Lawrence Liao; Larry A Allen; David J Whellan
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

5.  Analyzing composite outcomes in cardiovascular studies: traditional Cox proportional hazards versus quality-of-life-adjusted survival approaches.

Authors:  Dean T Eurich; Sumit R Majumdar; Finlay A McAlister; Ross T Tsuyuki; Yutaka Yasui; Jeffrey A Johnson
Journal:  Open Med       Date:  2010-02-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.